Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001815776-24-000060
Filing Date
2024-08-14
Accepted
2024-08-14 16:15:28
Documents
62
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q lenz-20240630.htm   iXBRL 10-Q 1390245
2 EX-10.1 lenz-2024pipexspaedgarvers.htm EX-10.1 263409
3 EX-31.1 exhibit311q224.htm EX-31.1 10746
4 EX-31.2 exhibit312q224.htm EX-31.2 10749
5 EX-32.1 exhibit321q224.htm EX-32.1 5357
6 EX-32.2 exhibit322q224.htm EX-32.2 5360
  Complete submission text file 0001815776-24-000060.txt   6235663

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lenz-20240630.xsd EX-101.SCH 36292
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT lenz-20240630_cal.xml EX-101.CAL 45322
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT lenz-20240630_def.xml EX-101.DEF 220771
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lenz-20240630_lab.xml EX-101.LAB 516119
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lenz-20240630_pre.xml EX-101.PRE 352842
64 EXTRACTED XBRL INSTANCE DOCUMENT lenz-20240630_htm.xml XML 594989
Mailing Address 445 MARINE VIEW AVE SUITE 320 DEL MAR CA 92014
Business Address 445 MARINE VIEW AVE SUITE 320 DEL MAR CA 92014 858-925-7000
LENZ Therapeutics, Inc. (Filer) CIK: 0001815776 (see all company filings)

EIN.: 844867570 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40532 | Film No.: 241208030
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)